Daily Roundup

XRF Scientific Ltd is firing on all cylinders. The scientific equipment company delivered a stellar Q2 performance with revenue jumping 38% to $21.1 million and profit before tax climbing 30% to $4.4 million. The growth came from strong demand across consumables and capital equipment sales, while their Orbis product line surged 66% to $2.4 million. The newly opened India office is already profitable, and precious metals product sales reached $9.6 million. Looking ahead, the company expects the December quarter to be even stronger, bolstered by new revenue from their CGA acquisition—which is on track to begin production in December.

Baby Bunting Group Ltd is hitting its stride in the retail space. The kids' retailer reported record sales of $556 million, up 6.5%, with an impressive gross margin of 41.2%. What's particularly noteworthy is the success of their store refurbishment program—17 stores have been overhauled and are delivering an average 20% sales lift. For the year ahead, the company is sticking with its guidance, expecting pro forma net profit after tax between $19 million and $21 million, assuming total sales of $585 million to $600 million and comparable store sales growth of 3% to 5%. The company also announced leadership changes, with Gary Levin stepping down and Richard Vincent joining the board.

PainChek is making serious headway in the US market. The health tech company has significantly expanded its footprint by securing contracts across 23 Sabra Health Care communities—up from just two facilities announced earlier this year. This expansion covers five separate operators and positions PainChek to tap into an estimated 1.2 million potential license opportunity in assisted living and memory care. The company is now focused on converting these 808 memory care licenses into implemented recurring revenue by the end of December.

Memphasys Ltd is experiencing impressive momentum. The company's quarterly invoiced revenues hit a record $211,000, representing a 41% jump from the previous quarter. International expansion is accelerating, with new distribution agreements signed across Poland, Nordic markets, and Central Asia. Regulatory approvals have also opened doors in Vietnam, Thailand, and Turkey. To fuel this growth, Memphasys secured a $3.5 million funding agreement with Peters Investments. The company is also exploring a potential FDA pathway for its Felix product, with pre-submission discussions planned to clarify US regulatory requirements.

Raiz Invest is dealing with historical tax compliance issues. The fintech platform has identified problems related to tax file number and Australian Business Number withholding and reporting obligations for certain funds since 2015. The company has engaged WTS Australia to conduct an independent review and has proactively notified the Australian Taxation Office and ASIC. While a remediation program is underway, Raiz has assured customers that their funds remain secure and no immediate action is required. The company will provide further updates as the review progresses.